Aberrant protein activity rewires lymphoma cells to survive BTK inhibitors, offering targe
A protein that can dial down oxidative stress in cells helps some cancers resist treatment with a widely used class of drugs called BTK inhibitors, according to a study led by investigators at Weill Cornell Medicine. The discovery points to a possible solution to the problem of B